SOURCE: Nuvilex, Inc.

Nuvilex, Inc.

December 16, 2013 09:15 ET

Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine

NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage clinical trials in advanced, inoperable pancreatic cancer that is. In an editorial that accompanied the findings of an epidemiological study of patients with pancreatic cancer published in the November 20 issue of the Journal of the National Cancer Institute (JNCI), treatments using the drug gemcitabine for the disease were put on notice and treatments not using gemcitabine alone or in combination with another drug as a treatment are being sought. Nuvilex has just such a treatment ready for late-phase clinical trials.

In that editorial, Dana Cardin, MD, MSCI, and Jordan Berlin, MD, from the Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center in Nashville, Tennessee, stated that more effective therapies will be needed to stem the rising tide of pancreatic cancer. This editorial is good news for Nuvilex in that both doctors agree with a 2007 NCI sponsored "state of the science" meeting that called for "a need to abandon the mindless propagation of the 'gemcitabine vs gemcitabine + your drug here' design used for over a decade in late-stage pivotal clinical trials."

Eli Lilly's (LLY) pancreatic cancer drug Gemzar® or gemcitabine has been the single-agent "gold standard" for the treatment of the disease since the FDA approved it in 1996, but just this year the FDA approved Celgene's (CELG) Abraxane® (a nanoparticle formulation of the widely used drug Taxol with albumin) in combination with gemcitabine as the new treatment of choice for those with advanced, inoperable pancreatic cancer. 

However, the NCI, and now both Drs. Cardin and Berlin, are calling for a solution that does not use gemcitabine as part of the treatment for the disease in hopes of improving median survival time over those seen with Eli Lilly and Celgene's treatments. As the calls grow louder for a better treatment, Nuvilex's COO, Dr. Gerry Crabtree says count his company in the hunt for a shot at a better solution.

Continue Reading:

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, Interviews and Feature Articles. For more information and to read disclaimers and disclosures:

Contact Information